---
title: "Achieve Life Sciences | 10-Q: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286089003.md"
datetime: "2026-05-12T11:23:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286089003.md)
  - [en](https://longbridge.com/en/news/286089003.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286089003.md)
---

# Achieve Life Sciences | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.19, beating the estimate of USD -0.2986.

EBIT: As of FY2026 Q1, the actual value is USD -10.49 M.

Achieve Life Sciences, Inc. focuses its operations on the development and commercialization of cytisinicline for nicotine independence .

#### Overall Financial Performance

-   **Net Loss**: Achieve Life Sciences, Inc. reported a net loss of - $10.2 million for the three months ended March 31, 2026, which improved from a net loss of - $12.8 million for the same period in 2025 .
-   **Accumulated Deficit**: The accumulated deficit reached - $270.4 million as of March 31, 2026 .
-   **Cash, Cash Equivalents, and Marketable Securities**: These totaled $29.3 million as of March 31, 2026 .
-   **Working Capital**: The company maintained a positive working capital balance of $19.2 million as of March 31, 2026 .

#### Cash Flow

-   **Net Cash Used in Operating Activities**: This was - $6.9 million for the three months ended March 31, 2026, an improvement from - $11.1 million in the prior year period .
-   **Net Cash Provided by Financing Activities**: This amounted to $21,000 for the three months ended March 31, 2026 .
-   **Net Cash Provided by Investing Activities**: This was $14.3 million for the three months ended March 31, 2026 .

#### Operational Metrics (Three Months Ended March 31, YoY Comparison)

-   **Research and Development (R&D) Expenses**: Decreased to $3.3 million in 2026 from $7.1 million in 2025, primarily due to a $3.3 million reduction in clinical trial costs and a - $1.9 million decrease in stock-based compensation expense, partially offset by a $0.6 million increase in manufacturing and supply chain costs .
-   **General and Administrative (G&A) Expenses**: Increased to $7.2 million in 2026 from $5.8 million in 2025, driven by $3.2 million in higher commercial launch preparation costs, $0.6 million in increased employee expenses, and $0.4 million in higher legal expenses, partially offset by a - $1.9 million decrease in stock-based compensation expense .
-   **Interest Income**: Remained stable at $0.3 million for both periods .
-   **Interest Expense**: Increased to $0.3 million in 2026 from $0.2 million in 2025 due to a higher average debt balance .
-   **Change in Fair Value of Contingent Consideration**: A gain of $0.3 million was recognized in 2026, compared to a loss of - $0.1 million in 2025, with the fair value estimated at $1.3 million as of March 31, 2026 .

#### Future Outlook and Strategy

Achieve Life Sciences, Inc. expects to receive a Complete Response Letter (CRL) from the FDA on or before June 20, 2026, for cytisinicline, which will delay NDA approval . The company plans to resubmit the NDA in the fourth quarter of 2026 and anticipates a commercial launch of cytisinicline in the first half of 2027 . The U.S. market commercialization strategy involves independent marketing and sales efforts, utilizing AI tools and an integrated agency partnership .

#### Liquidity and Capital Resources

In April 2026, Achieve Life Sciences, Inc. completed a private placement, generating gross proceeds of approximately $180.0 million and estimated net proceeds of approximately $168.6 million after expenses . The company relies on its ability to raise additional funds to support ongoing clinical development and commercialization activities .

### Related Stocks

- [ACHV.US](https://longbridge.com/en/quote/ACHV.US.md)

## Related News & Research

- [Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment | ACHV Stock News](https://longbridge.com/en/news/286952863.md)
- [Achieve Life Sciences Announces Up to $354 Million Private Placement | ACHV Stock News](https://longbridge.com/en/news/283004765.md)
- [Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 | WVE Stock News](https://longbridge.com/en/news/286925108.md)
- [16:52 ETNexusTek Named a Contender in ISG Provider Lens® Life Sciences Digital Services 2026 Report](https://longbridge.com/en/news/286818120.md)
- [Jacobs Growth Could Improve on Data Centers, Life Sciences Demand, RBC Says](https://longbridge.com/en/news/286945689.md)